Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
A search of ClinicalTrials.gov as of January 2025 shows no phase II or III trials registered for BPC-157 in GI healing
The MHRA actively warns against purchasing and using unlicensed injectable medicines from unregulated online sources, citing risks of contamination, incorrect labelling, and unknown purity
Padua, L
The delayed release formula is intended to reach the lower intestines without succumbing to the harsh environment of the upper digestive system
Key Takeaways Standard concentration: Mix 10mg retatrutide with 2-3mL BAC water for easy dosing Injection technique: Add water slowly down the vial wall, never directly onto powder Mixing method: Gently swirl (never shake) until fully dissolved Storage: Refrigerate at 36-46F (2-8C) for up to 28-60 days Use our free calculator to determine exact insulin units for your dose Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials or compounding pharmacies
US$ 27.46
US$ 20.29
US$ 28.93